InvestSMART

Cambium Bio Limited (ASX:CMB)

ALERT: Price-sensitive ASX Announcement for CMB
Current share price for CMB : $0.415 -0.05 (-10.75%)+
Announcement
Release
5 Sep 2025 11:37AM
Price at Release
$0.465
Full Release
download
Summary
Cambium Bio Limited has signed a Memorandum of Understanding (MoU) with Benta SAS, a leading French pharmaceutical company, to develop and commercialize Elate Ocular® for dry eye disease in Europe and the Middle East. This strategic partnership grants Benta exclusive rights in these territories and involves either a direct licensing agreement, the formation of a new corporate entity, or a joint venture. Cambium will provide exclusive license rights and necessary technology transfer to Benta. The partnership aims to leverage Benta's extensive experience and infrastructure in blood-derived therapeutics and ophthalmology. This is Cambium's second licensing agreement for its human platelet lysate technology within three days, highlighting its commercial potential and scalability. The definitive agreements are to be executed within four months, followed by regulatory submissions and setup for manufacturing.
Key Points
  • Cambium Bio signs MoU with Benta SAS.
  • Exclusive commercialization rights for Elate Ocular® in Europe and Middle East.
  • Partnership involves technology transfer and potential joint venture.
  • Benta SAS has extensive experience in blood-derived therapeutics.
  • This is the second licensing deal in three days for Cambium's technology.
  • Definitive agreements execution and regulatory submissions planned within four months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.